Puerto Rican company Galephar PR Inc has asked the Marketletter to clarify a recent announcement regarding its "sale" to Canadian group Biovail (Marketletter September 25).
In fact what has happened, Galephar's chairman Ph Baudier explains, is that it has sold its Puerto Rico high-technology production plant to Biovail, with which it has had close collaboration in the registration of Galephar's patented diltiazem controlled-release product Tiazac, in order that the Canadian firm could control production for the American market.
The Galephar Group, or rather its Belgian parent company Laboratoires SMB, however, still retains all patents worldwide and production rights outside the USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze